Trial Outcomes & Findings for Impact of KUVAN® on Gastric Relaxation in Women With Diabetic Gastroparesis. (NCT NCT01135186)

NCT ID: NCT01135186

Last Updated: 2019-09-10

Results Overview

Gastric Accommodation refers to the reflexive relaxation of the upper stomach after swallowing as measured by the Satiety Test at baseline, 4 weeks, and 8 weeks. Increased gastric accommodation is considered a positive outcome.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

9 participants

Primary outcome timeframe

Baseline, 4 Weeks, 8 Weeks

Results posted on

2019-09-10

Participant Flow

9 women with moderate to severe gastroparesis were enrolled at medical clinic.

Participant milestones

Participant milestones
Measure
Open Label Study
sapropterin dihydrochloride sapropterin dihydrochloride: sapropterin dihydrochloride: 10mg/kg/day
Overall Study
STARTED
9
Overall Study
COMPLETED
9
Overall Study
NOT COMPLETED
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Impact of KUVAN® on Gastric Relaxation in Women With Diabetic Gastroparesis.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Open Label Study
n=9 Participants
sapropterin dihydrochloride sapropterin dihydrochloride: sapropterin dihydrochloride: 10mg/kg/day (week 1 through week 4) sapropterin dihydrochloride: sapropterin dihydrochloride: 20mg/kg/day (week 5 through week 8)
Age, Categorical
<=18 years
0 Participants
n=99 Participants
Age, Categorical
Between 18 and 65 years
9 Participants
n=99 Participants
Age, Categorical
>=65 years
0 Participants
n=99 Participants
Age, Continuous
42.56 years
STANDARD_DEVIATION 15.03 • n=99 Participants
Sex: Female, Male
Female
9 Participants
n=99 Participants
Sex: Female, Male
Male
0 Participants
n=99 Participants
Region of Enrollment
United States
9 participants
n=99 Participants

PRIMARY outcome

Timeframe: Baseline, 4 Weeks, 8 Weeks

Gastric Accommodation refers to the reflexive relaxation of the upper stomach after swallowing as measured by the Satiety Test at baseline, 4 weeks, and 8 weeks. Increased gastric accommodation is considered a positive outcome.

Outcome measures

Outcome measures
Measure
Open Label Study
n=9 Participants
sapropterin dihydrochloride sapropterin dihydrochloride: sapropterin dihydrochloride: 10mg/kg/day
Gastric Accommodation
Baseline
322.22 ml
Standard Deviation 137.18
Gastric Accommodation
4 Weeks
402.78 ml
Standard Deviation 197.03
Gastric Accommodation
8 Weeks
450.63 ml
Standard Deviation 301.50

SECONDARY outcome

Timeframe: Baseline, 4 Weeks, 8 Weeks

Change in symptom severity over the past 2 weeks as measured by the patient reported Gastroparesis Cardinal Symptom Index (GCSI) The GCSI is composed of 9 questions. Each question asks about symptom severity on a scale of 1-5 listed below. 0=None 1= Very mild 2= Mild 3=Moderate 4=Severe 5= Very severe The 9 scores are summed together for cumulative GCSI score. The minimum cumulative score is '"0" and the maximum cumulative score is "45." Once we calculated the cumulative score for each participant, we took the average of all participants cumulative scores giving us the sample mean. This was done at baseline, week 4, and week 8. Higher total scores indicate higher symptom severity. Lower total scores indicate lower symptom severity.

Outcome measures

Outcome measures
Measure
Open Label Study
n=9 Participants
sapropterin dihydrochloride sapropterin dihydrochloride: sapropterin dihydrochloride: 10mg/kg/day
Secondary Outcome Measures Will Include Change in Symptom Severity.
Baseline
32.00 units on a scale
Standard Deviation 8.67
Secondary Outcome Measures Will Include Change in Symptom Severity.
4 Weeks
23.25 units on a scale
Standard Deviation 13.91
Secondary Outcome Measures Will Include Change in Symptom Severity.
8 Weeks
23.67 units on a scale
Standard Deviation 13.91

SECONDARY outcome

Timeframe: Baseline, 4 Weeks, 8 Weeks

Quality of life as impacted by patients with upper gastrointestinal disorders (PAGI-QOL) The PAGI-QOl is composed of 30 questions. Each question asks about the degree to which a patient's quality of life is impacted by upper gastrointestinal disorders. Questions measure quality of life impact on a scale of 1-5 listed below. 0=none of the time, 1=a little of the time, 2=some of the time, 3=a good bit of the time, 4= most of the time, 5= all of time The 30 items are summed together for a cumulative PAGI-QOL score. The minimum cumulative score is "0" and the maximum score is "150." Once we calculated the cumulative score for each participant, we took the average of all participants cumulative scores giving us the sample mean. This was done at baseline, week 4, and week 8. Lower scores indicate an improved overall quality of life. Higher scores indicate a diminished overall quality of life.

Outcome measures

Outcome measures
Measure
Open Label Study
n=9 Participants
sapropterin dihydrochloride sapropterin dihydrochloride: sapropterin dihydrochloride: 10mg/kg/day
Secondary Outcome Measures Will Include Change in Quality of Life.
Baseline
91.22 units on a scale
Standard Deviation 28.27
Secondary Outcome Measures Will Include Change in Quality of Life.
4 Weeks
61.29 units on a scale
Standard Deviation 37.83
Secondary Outcome Measures Will Include Change in Quality of Life.
8 Weeks
60.50 units on a scale
Standard Deviation 40.90

SECONDARY outcome

Timeframe: Baseline, 4 Weeks, 8 Weeks

Symptom severity as measured by the Patient Assessment of Upper Gastrointestinal Disorder- Symptom Severity Index. (PAGI-SYM) The PAGI-SYM is compose of 20 questions. Each question can be answered on a scale of 1-5 (below) 0 = none, 1=very mild, 2=mild, 3=moderate, 4=severe, 5=very severe Cumulative scores were calculated by summing all 20 questions. The minimum cumulative scores would be "0" while the maximum cumulative score would be "100" Once we calculated the cumulative score for each participant, we took the average of all the cumulative scores giving us the sample mean. This was done at baseline, week 4, and week 8. Lower score indicates decreased symptom severity. Higher score indicates increased symptom severity.

Outcome measures

Outcome measures
Measure
Open Label Study
n=9 Participants
sapropterin dihydrochloride sapropterin dihydrochloride: sapropterin dihydrochloride: 10mg/kg/day
Secondary Outcome Measures Will Include Change in Symptom Severity as Measured by the Patient Assessment of Gastrointestinal Disorder-Symptom Severity Index Disorders Symptom Severity Index (PAGI-SYM)
Baseline
54.89 units on a scale
Standard Deviation 17.14
Secondary Outcome Measures Will Include Change in Symptom Severity as Measured by the Patient Assessment of Gastrointestinal Disorder-Symptom Severity Index Disorders Symptom Severity Index (PAGI-SYM)
4 Weeks
41.50 units on a scale
Standard Deviation 23.08
Secondary Outcome Measures Will Include Change in Symptom Severity as Measured by the Patient Assessment of Gastrointestinal Disorder-Symptom Severity Index Disorders Symptom Severity Index (PAGI-SYM)
8 Weeks
34.50 units on a scale
Standard Deviation 19.71

Adverse Events

Open Label Study

Serious events: 1 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
Open Label Study
n=9 participants at risk
sapropterin dihydrochloride sapropterin dihydrochloride: sapropterin dihydrochloride: 10mg/kg/day (week 1-4) 20 mg/kg/day (week 5-8)
Gastrointestinal disorders
Hospitalization for gastroparesis flareup
11.1%
1/9 • Number of events 1

Other adverse events

Adverse event data not reported

Additional Information

Dr. Linda Anh B. Nguyen

Stanford University

Phone: 650-736-5555

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place